Get to know our clinical trials
Phase I clinical trial of RO7589831 in participants with advanced solid tumors.
THE MAIN OBJECTIVE OF THIS TRIAL IS TO TEST WHETHER RO7589831 ADMINISTERED AT DIFFERENT DOSES HAS EFFECTS (GOOD OR BAD), AS WELL AS WHAT HAPPENS TO RO7589831 ONCE IT HAS ENTERED THE BODY AND HOW IT ACTS ON THE BODY AND ITS DISEASE.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- PHASE I OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF RO7589831 IN PARTICIPANTS WITH ADVANCED SOLID TUMORS CARRYING MICROSATELLITE INSTABILITY (MSII) AND/OR DEFICIENCY IN MISMATCH REPAIR (DMMR) SYSTEM
- Code EudraCT: 2023-503170-20-00
- Protocol number: BP44474
- Promoter: Roche Farma, S.A.
- Molecule/Drug: RO7589831
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.